Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study

There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated the safety of remdesivir administration for COVID-19 patients with estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between March 2020 and April 2022 at Tosei General Hospital, Japan. Propensity score matching was performed between patients with eGFR ≤ 30 mL/min and eGFR >30 mL/min with remdesivir administration. The primary outcome was 30-day mortality after the first administration. Adverse events, including development of acute kidney injury (AKI), liver function disorder, anemia, and thrombocytopenia 48 h after the end of remdesivir administration, were evaluated. After propensity score matching, 23 patients were selected from each group. There were no differences in the 30-day mortality (risk ratio [RR] 1.00; 95% confidence interval [CI] 0.18–5.56). Development of AKI and liver function disorder was not statistically different between the two groups (RR 1.05; 95% CI 0.96–1.14 and RR 0.48; 95% CI 0.04–5.66, respectively). There was no trend toward a significant increase in adverse events in the eGFR < 30 mL/min group and severe renal dysfunction had little effect on the safety of remdesivir treatment.

[1]  Connie M. Rhee,et al.  Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) , 2022, Diabetes care.

[2]  M. Sise,et al.  A Propensity Score–Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease , 2021, Kidney360.

[3]  J. Skarbinski,et al.  Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.

[4]  T. Hirai,et al.  Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction , 2021, CPT: pharmacometrics & systems pharmacology.

[5]  B. Cicali,et al.  A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort , 2020, Antimicrobial Agents and Chemotherapy.

[6]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[7]  R. Bhattacharyya,et al.  Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[8]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[9]  S. Cammarata,et al.  Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment , 2018, Journal of clinical pharmacology.

[10]  R. Turner,et al.  Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: A systematic review. , 2015, International journal of antimicrobial agents.

[11]  高橋 聡,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .

[12]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.